1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. . Kidney Int 2013(Suppl. 3):1–150.
2.Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, Chen J, He J: A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015, 88(5):950–957.
3.Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai C-Y, Floyd T, Al-Aly Z: Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018, 94(3):567–581.
4.United States Renal Data System. 2019 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2019.
5.Bowe B, Xie Y, Li T, Mokdad AH, Xian H, Yan Y, Maddukuri G, Al-Aly Z: Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016: An Analysis of the Global Burden of Disease Study. JAMA Netw Open 2018, 1(7):e184412-e184412.
6.Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X et al: Prevalence of chronic kidney disease in China: a cross-sectional survey. The Lancet 2012, 379(9818):815–822.
7.Zhang L, Zhao MH, Zuo L, Wang Y, Yu F, Zhang H, Wang H, Group C-NW: China Kidney Disease Network (CK-NET) 2015 Annual Data Report. Kidney Int Suppl (2011) 2019, 9(1):e1-e81.
8.Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, Lv J, Garg AX, Knight J et al: Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet (London, England) 2015, 385(9981):1975–1982.
9.McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM: Projecting ESRD Incidence and Prevalence in the United States through 2030. J Am Soc Nephrol 2019, 30(1):127–135.
10.Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, Kanaka-Gantenbein C, Tentolouris N, Papassotiriou I: The clinical impact of growth differentiation factor–15 in heart disease: A 2019 update. Crit Rev Clin Lab Sci 2019:1–12.
11.Mullican SE, Rangwala SM: Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond. Trends Endocrinol Metab 2018, 29(8):560–570.
12.Mullican SE, Lin-Schmidt X, Chin C-N, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-Mason TD et al: GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nature Medicine 2017, 23(10):1150–1157.
13.Farhan S, Freynhofer MK, Brozovic I, Bruno V, Vogel B, Tentzeris I, Baumgartner-Parzer S, Huber K, Kautzky-Willer A: Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study. Cardiovasc Diabetol 2016, 15:60.
14.Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, Herzog EL, Kang I, Pisani MA, Yu S et al: GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell 2019, 178(5):1231–1244.e1211.
15.Louca M, Gkretsi V, Stylianopoulos T: Coordinated Expression of Ras Suppressor 1 (RSU–1) and Growth Differentiation Factor 15 (GDF15) Affects Glioma Cell Invasion. Cancers 2019, 11(8).
16.Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J: GDF–15, iron, and inflammation in early chronic kidney disease among elderly patients. Int Urol Nephrol 2016, 48(6):839–844.
17.Nair V, Robinson-Cohen C, Smith MR, Bellovich KA, Bhat ZY, Bobadilla M, Brosius F, de Boer IH, Essioux L, Formentini I et al: Growth Differentiation Factor–15 and Risk of CKD Progression. J Am Soc Nephrol 2017, 28(7):2233–2240.
18.Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, Hedelin M, Clark J, Stattin P, Meyers DA et al: H6D polymorphism in macrophage-inhibitory cytokine–1 gene associated with prostate cancer. J Natl Cancer Inst 2004, 96(16):1248–1254.
19.Hayes VM, Severi G, Southey MC, Padilla EJ, English DR, Hopper JL, Giles GG, Sutherland RL: Macrophage inhibitory cytokine–1 H6D polymorphism, prostate cancer risk, and survival. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006, 15(6):1223–1225.
20.Wang X, Yang X, Sun K, Chen J, Song X, Wang H, Liu Z, Wang C, Zhang C, Hui R: The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond) 2009, 118(2):137–145.
21.Chen Z, Xie F, Ma G, Feng Y, Qian Q, Liu N: Study of the association between growth differentiation factor 15 gene polymorphism and coronary artery disease in a Chinese population. Mol Biol Rep 2011, 38(8):5085–5091.
22.Wang J, Li W, Wang Y, Li C, Ding M, Zhang H, Lai M: The H6D genetic variation of GDF15 is associated with genesis, progress and prognosis in colorectal cancer. Pathol Res Pract 2015, 211(11):845–850.
23.Lawton LN, Bonaldo MF, Jelenc PC, Qiu L, Baumes SA, Marcelino RA, de Jesus GM, Wellington S, Knowles JA, Warburton D et al: Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta. Gene 1997, 203(1):17–26.
24.Chen J, Fan M, Wang J, Huang L, Xie L, Zhang J, Liu D, Zhang J, Xu X: Application of Radiomics Information Captured from PET and CT to Predict Outcomes of Stereotactic Ablative Radiation Therapy in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol 2017, 99(2):E454-E454.
25.TA Z, X J, EC H, SA M, AF E, LG K: Growth differentiation factor–15/macrophage inhibitory cytokine–1 induction after kidney and lung injury. Shock (Augusta, Ga) 2005, 23(6):543–548.
26.Bidadkosh A, Lambooy SPH, Heerspink HJ, Pena MJ, Henning RH, Buikema H, Deelman LE: Predictive Properties of Biomarkers GDF–15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy. Diabetes Care 2017, 40(6):784–792.
27.Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I, Brosius F, Gadegbeku C, Gipson D, Hawkins J et al: GDF–15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation 2018, 72(4):519–528.
28.Fairlie WD, Russell PK, Wu WM, Moore AG, Zhang HP, Brown PK, Bauskin AR, Breit SN: Epitope mapping of the transforming growth factor-beta superfamily protein, macrophage inhibitory cytokine–1 (MIC–1): identification of at least five distinct epitope specificities. Biochemistry 2001.
29.Jiang J, Thalamuthu A, Ho JE, Mahajan A, Ek WE, Brown DA, Breit SN, Wang TJ, Gyllensten U, Chen M-H et al: A Meta-Analysis of Genome-Wide Association Studies of Growth Differentiation Factor–15 Concentration in Blood. Front Genet 2018, 9:97–97.
30.Li S, Ma YM, Zheng PS, Zhang P: GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. Journal of experimental & clinical cancer research: CR 2018, 37(1):80.
31.Griner SE, Joshi JP, Nahta R: Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochemical pharmacology 2013, 85(1):46–58.
32.Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, Ballman KK et al: The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nature medicine 2017, 23(10):1215–1219.
33.Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross J, Cimino I, Yang M, Welsh P, Virtue S et al: GDF15 mediates the effects of metformin on body weight and energy balance. Nature 2019:10.1038/s41586–41019–41911-y.